Research and Markets: Available Now: Thought Leader Insight & Analysis: Psoriasis

Business Wire, May 28, 2008

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c93073) has announced the addition of "Thought Leader Insight & Analysis: Psoriasis" to their offering.

Psoriasis Thought Leader Panel #13 continues the researcher's discussion with US and European Thought Leaders. During these conversations the Panelists offered their insight into the following:

- How to balance long-term toxicities (liver, cardiovascular, infection) against therapeutic benefits.

- How are differences in the labels affecting Humira and Enbrel use in the US and in Europe? How are these brands being positioned in expectation of ustekinumab's launch?

- Is there a need for new anti-TNFs; golimumab, certolizumab, apremilast?

- What is the product profile and positioning for an oral anti-psoriatic therapy?

- How to approach combination therapy, and sequenced induction / maintenance.

- What is the evolving role of methotrexate in the treatment of psoriasis?

- How do ustekinumab and ABT-874 compare for psoriasis and psoriatic arthritis? How do they compare to anti-TNF therapy?

- Which is a better research target: IL23 or IL17?

- New mechanisms: oral and topical JAK and p38 MAP kinase inhibitors, PDE4, calcineurin inhibitors, anti-PNP.

CONTENTS:

Executive Summary

- Bulleted Highlights

Key Findings

Cardiovascular Risk

Orals

Combinations

Anti-TNF

- Enbrel (etanercept; Amgen/Wyeth)

- Humira (adalimumab; Abbott)

- Remicade (infliximab; Centocor)

- Golimumab (Centocor / Schering-Plough)

- Cimzia (certolizumab; UCB)

- Apremilast (Celgene)

- AN2728(Anacor)

Methotrexate

- Metoject (methotrexate prefilled syringes; Medac / Gebro) p40; Anti-IL-12 / Anti-IL-23

- Ustekinumab CNTO-1275 (Centocor; Janssen-Cilag; Schering-Plough; Essex)

- ABT-874 (Abbott)

P19 Antibodies.

Anti-IL-17

- AIN-457 (Novartis)

- IL-17RC (Zymogenetics / Merck Serono)

Anti-CD-11a / LFA-1

- Raptiva (efalizumab; Merck-Serono / Genentech)

p-38 MAPK

- BMS-582949 (BMS)

Fumaric Acid Esters

- Fumaderm / Panaderm / Panaclar (dimethyl fumarate; Biogen)

Calcineurin Inhibitors

- Voclosporin (ISA247; Isotechnika)

JAK Inhibitors

- CP-690550 (Pfizer)

- INCB-18424 (Incyte)

CTLA-4

- Orencia (abatacept; BMS)

PDE4

- ELB-353(Elbion NV)

Anti-PNP (purine nucleoside phosphorylase)

- BCX-4208/R3421 (Roche / BioCryst)

Topical Steroids

- Clobex (clobetasol; Galderma)

Thought-Leader Discussions

- Interview OHIID02014

- Interview OHIID02015

- Interview OHIID02016

- Interview OHIID02017

- Interview OHIID02018

- Interview OHIID02019

For more information visit http://www.researchandmarkets.com/reports/c93073